Spots Global Cancer Trial Database for pembrolizumab 200 mg iv every 3 weeks
Every month we try and update this database with for pembrolizumab 200 mg iv every 3 weeks cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | NCT04230954 | Cervical Cancer Recurrent Cervi... Metastatic Cerv... Persistent Cerv... | Cabozantinib 40... Pembrolizumab 2... | 18 Years - | University of South Alabama |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
